Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.
- Others:
- Laboratoire de Biochimie ; Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital Cimiez [Nice] (CHU)
- Laboratoire des Maladies Héréditaires du Métabolisme ; Groupement Hospitalier Lyon-Est (GHE) ; Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)
- Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- This work was supported by Centre Hospitalier Universitaire de Nice, Université de Nice Sophia-Antipolis, INSERM, and Conseil Général des Alpes-Maritimes for the acquisition of the MALDI TOF/TOF mass spectrometer (Appel d'Offre Santé, 2007).
Description
BACKGROUND: Oligosaccharidoses, which belong to the lysosomal storage diseases, are inherited metabolic disorders due to the absence or the loss of function of one of the enzymes involved in the catabolic pathway of glycoproteins and indirectly of glycosphingolipids. This enzymatic deficiency typically results in the abnormal accumulation of uncompletely degraded oligosaccharides in the urine. Since the clinical features of many of these disorders are not specific for a single enzyme deficiency, unambiguous screening is critical to limit the number of costly enzyme assays which otherwise must be performed. METHODS: Here we provide evidence for the advantages of using a MALDI-TOF/TOF (matrix-assisted laser desorption ionization time-of-flight) mass spectrometric (MS) method for screening oligosaccharidoses. Urine samples from previously diagnosed patients or from unaffected subjects were randomly divided into a training set and a blind testing set. Samples were directly analyzed without prior treatment. RESULTS: The characteristic MS and MS/MS molecular profiles obtained allowed us to identify fucosidosis, aspartylglucosaminuria, GM1 gangliosidosis, Sandhoff disease, α-mannosidosis, sialidosis and mucolipidoses type II and III. CONCLUSIONS: This method, which is easily run in less than 30 minutes, is performed in a single step, and is sensitive and specific. Invaluable for clinical chemistry purposes this MALDI-TOF/TOF mass spectrometry procedure is semi-automatizable and suitable for the urinary screening of oligosacharidoses.
Abstract
International audience
Additional details
- URL
- https://inserm.hal.science/inserm-00945684
- URN
- urn:oai:HAL:inserm-00945684v1
- Origin repository
- UNICA